


What is claimed is:

1. A compound of Formula (I):

5



(I)

wherein:

10 A is selected from: nitrogen, -C-halogen and -CH;

L^1 is selected from the group consisting of a bond, -O-, -N(R^5)-, -S-, -S(O)-, -S(O₂)-, alkyl, and -N(R^5)C(O)-;

15 L^2 is selected from the group consisting of a bond, -O-, heterocycle, -N(R^5)-, -N(R^5)C(O)-, -S-, -S(O)-, -S(O₂)-, and -C(O)N(R^5)-;

L^3 is alkyl, wherein the alkyl is optionally substituted with one or two substituents independently selected from the group consisting of amino,

20 methylamino, dimethylamino, oxo, and hydroxy;

L^6 is selected from the group consisting of a bond, -O-, -N(R^5)-, -S-, -S(O)-, -S(O₂)-, alkyl, and -N(R^5)C(O)-;

25 R^1 is selected from the group consisting of aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocycle and substituted heterocycle;

R^2 is selected from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, and a cyclic or polycyclic aromatic ring

30 containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one

or more substituents selected from the group consisting of: alkyl, substituted alkyl, trifluoroalkoxy, C₁-C₁₂aryl, aryloxy, -O(CH₂)_qR³¹, -NHC(O)-NHR⁴¹, -C(O)R⁴³, substituted cycloalkyl, substituted C₁-C₁₂aryl, heterocycle, substituted heterocycle, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, -C(O)OR⁷, -C(O)NR⁸R⁹, -S(O)₂NR⁸R⁹, and -S(O)_nR⁷,
5 where n is 0-2, q is 1-6,
R⁷ is hydrogen, alkyl, cycloalkyl, C₁-C₁₂aryl, substituted alkyl, substituted cycloalkyl and substituted C₁-C₁₂aryl,
R³¹ is C₁-C₁₂aryl, cycloalkyl and heterocycle, each of which is optionally substituted with from 1 to 4 substituents selected from: halogen, alkyl,
10 hydroxyalkyl, alkoxy, acyloxy, amino, methylamino, dimethylamino, N-acylamino, hydroxy, nitro, tetrazole, cyano, oxo and trifluoromethyl,
R⁴¹ is selected from hydrogen, C₁-C₁₂aryl, cycloalkyl and heterocycle, wherein C₁-C₁₂aryl, cycloalkyl and heterocycle are optionally substituted
15 with from 1 to 4 substituents selected from: halogen, alkyl, hydroxyalkyl, alkoxy, amino, methylamino, dimethylamino, hydroxy, nitro, tetrazole, cyano, oxo and trifluoromethyl,
R⁴³ is selected from C₁-C₁₂aryl, cycloalkyl and heterocycle, each of which is optionally substituted with from 1 to 4 substituents selected from:
20 halogen, hydroxyalkyl, alkoxy, amino, methylamino, dimethylamino, hydroxy, nitro, tetrazole, cyano, oxo and trifluoromethyl, and
R⁸ and R⁹ are independently hydrogen, cycloalkyl, C₁-C₁₂aryl, substituted cycloalkyl, substituted C₁-C₁₂aryl, alkyl or alkyl substituted
25 with one or more substituents selected from the group consisting of:
alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, -C(O)OR¹⁰, -S(O)_nR¹⁰, -C(O)NR¹⁰R¹¹, -S(O)₂NR¹⁰R¹¹, nitro, cyano, cycloalkyl,
substituted cycloalkyl, halogen, aryl, and substituted aryl,
30 or R⁸ and R⁹ taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally substituted with one or more substituents selected from amino, methylamino and dimethylamino,
35 where R¹⁰ and R¹¹ are independently hydrogen, alkyl, cycloalkyl, C₁-C₁₂aryl, substituted alkyl, substituted cycloalkyl and substituted C₁-C₁₂aryl, and n is 0-2,
and when L⁶ is a bond, R² can additionally be halogen;

R³ and R⁶ are independently selected from the group consisting of hydrogen, amino, methylamino, dimethylamino, aryl, substituted aryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, -S-C₁-C₁₂aryl, -O-C₁-C₁₂aryl, -OalkylC₁-C₁₂aryl, aryloxy, substituted aryloxy and arylalkoxy; and

5

R⁴ is selected from the group consisting of hydrogen and halogen;

where R⁵ is selected from the group consisting of hydrogen, -S(O)₂CH₃, -S(O)₂H and alkyl;

10

provided that when,

R¹ is azaindazole, substituted azaindazole, 1H-thienopyrazole, substituted 1H-thienopyrazole, benzamide, substituted benzamide, phenylethanone, substituted phenylethanone, thiophene, substituted thiophene, furan or substituted furan,

15

R² may additionally be hydrogen;

further provided that when

20

R¹ is isoquinoline,

R² is not furyl or alkyl.

2. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (I), as described in claim 1.

25

3. The compound of Formula (I), as claimed in claim 1,

wherein

30

A is selected from: nitrogen, -C-halogen and -CH;

35

L¹ is selected from the group consisting of a bond, -O-, -N(R⁵)-, -S-, -S(O)-, -S(O₂)-, alkyl, and -N(R⁵)C(O)-;

40

L² is selected from the group consisting of a bond, -O-, heterocycle, -N(R⁵)-

45

, -N(R⁵)C(O)-, -S-, -S(O)-, -S(O₂)-, and -C(O)N(R⁵)-;

5 L³ is alkyl, wherein the alkyl is optionally substituted with one or two substituents independently selected from the group consisting of amino, methylamino, dimethylamino, oxo, and hydroxy;

5 L⁶ is a bond;

10 R¹ is selected from the group consisting of C₁-C₁₂aryl and substituted C₁-C₁₂aryl;

15 R² is selected from alkyl, substituted alkyl, halogen, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, and C₁-C₁₂aryl optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, trifluoroalkoxy, C₁-C₁₂aryl, aryloxy, -O(CH₂)_qR³¹, -NHC(O)-NHR⁴¹, -C(O)R⁴³, hydroxy, alkoxy, cycloalkyl, N-acylamino, nitro and halogen,

20 where q is 1-6,

25 R³¹ is C₁-C₁₂aryl, cycloalkyl and heterocycle, each of which is optionally substituted with from 1 to 4 substituents selected from: halogen, alkyl, hydroxyalkyl, alkoxy, acyloxy, amino, methylamino, dimethylamino, N-

30 acylamino, hydroxy, nitro, tetrazole, cyano, oxo and trifluoromethyl,

35 R⁴¹ is selected from hydrogen, C₁-C₁₂aryl, cycloalkyl and heterocycle, wherein C₁-C₁₂aryl, cycloalkyl and heterocycle are optionally substituted with from 1 to 4 substituents selected from: halogen, alkyl, hydroxyalkyl, alkoxy, amino, methylamino, dimethylamino, hydroxy, nitro, tetrazole, cyano, oxo and trifluoromethyl,

40 R⁴³ is selected from C₁-C₁₂aryl, cycloalkyl and heterocycle, each of which is optionally substituted with from 1 to 4 substituents selected from: halogen, hydroxyalkyl, alkoxy, amino, methylamino, dimethylamino, hydroxyl, nitro, tetrazole, cyano, oxo and trifluoromethyl,

45 R³ and R⁶ are independently selected from the group consisting of hydrogen, amino, methylamino, dimethylamino, aryl, substituted aryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, -S-C₁-C₁₂aryl, aryloxy and arylalkoxy; and

50 R⁴ is selected from the group consisting of hydrogen and halogen;

where R^5 is selected from the group consisting of hydrogen, $-S(O)_2CH_3$, $-S(O)_2H$ and alkyl;

provided that when,

5 R^1 is azaindazole, substituted azaindazole, 1H-thienopyrazole, substituted 1H-thienopyrazole, benzamide, substituted benzamide, phenylethanone, substituted phenylethanone, thiophene, substituted thiophene, furan or substituted furan,

R^2 may additionally be hydrogen;

10

further provided that when

R^1 is isoquinoline,


R^2 is not furyl or alkyl.

15

4. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (I), as described in claim 3.

5. A compound of Claim 1 represented by the following Formula (II):

20



(II)

wherein:

A is selected from nitrogen, $-CF$ and $-CH$;

25

L^4 is selected from the group consisting of a bond, heterocycle, $-O-$, and $-NH-$;

30 L^5 is alkyl, wherein the alkyl is optionally substituted with one or two substituents independently selected from the group consisting of amino, oxo, and hydroxy;

R¹⁴ is selected from the group consisting of C₁-C₁₂aryl, and substituted C₁-C₁₂aryl;

R¹⁵ is selected from alkyl, substituted alkyl, halogen, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, C₁-C₁₂aryl and C₁-C₁₂aryl optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, trifluoroalkoxy, aryloxy, -O(CH₂)_qR³¹, -NHC(O)-NHR⁴¹, -C(O)R⁴³, hydroxy, alkoxy, acyloxy, amino, cycloalkyl, N-acylamino, nitro, cyano and halogen,

10 where q is 1-6,
R³¹ is C₁-C₁₂aryl optionally substituted with from 1 to 4 substituents selected from: halogen, alkyl, hydroxyalkyl, alkoxy, and hydroxy,
R⁴¹ is selected from hydrogen and C₁-C₁₂aryl optionally substituted with from 1 to 4 substituents selected from: halogen, alkyl, hydroxyalkyl, alkoxy, and hydroxy,
15 R⁴³ is C₁-C₁₂aryl substituted with from 1 to 4 substituents selected from: halogen, hydroxyalkyl, alkoxy, and hydroxy, and

R¹⁶ and R¹⁷ are independently selected from the group consisting of
20 hydrogen, C₁-C₁₂aryl, substituted C₁-C₁₂aryl, heterocycle, cycloalkyl, -S-C₁-C₁₂aryl, and C₁-C₁₂arylalkoxy;

provided that when,

R¹⁴ is azaindazole, substituted azaindazole, 1H-thienopyrazole, substituted 1H-thienopyrazole, benzamide, substituted benzamide, phenylethanone, substituted phenylethanone, 2-pyridinecarboxamide, substituted 2-pyridinecarboxamide, (methylsulfonyl)benzene, substituted (methylsulfonyl)benzene, thiophene, substituted thiophene, furan or substituted furan,
30 R¹⁵ may additionally be hydrogen;

further provided that when

R¹⁴ is isoquinoline,
R¹⁵ is not furyl or alkyl.

35 6. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (II), as described in claim 5.

7. A compound of Formula (II), as described in claim 5:

wherein

5 A is selected from nitrogen, -CF and -CH;

. L⁴ is selected from the group consisting of a bond, -O-, and -NH-;

10 L⁵ is alkyl, wherein the alkyl is substituted with one or two substituents
independently selected from the group consisting of amino, oxo, and
hydroxy;

15 R¹⁴ is selected from phenyl, pyridine, indazole, 7-azaindole, quinoline,
isoquinoline, substituted phenyl, substituted pyridine, substituted indazole,
substituted 7-azaindole, substituted quinoline and substituted isoquinoline;

20 R¹⁵ is selected from cycloalkyl, substituted cycloalkyl, phenyl, pyridine,
thiophene, furan, pyrrole, indazole, quinoline, isoquinoline, 7-azaindole,
substituted phenyl, substituted pyridine, substituted thiophene, substituted
furan, substituted indazole, substituted quinoline, substituted 7-azaindole
and substituted isoquinoline; and

25 R¹⁶ and R¹⁷ are independently selected from the group consisting of
hydrogen, indole, substituted indole, azaindole, substituted azaindole,
naphthalene, substituted naphthalene, benzofuran, substituted
benzofuran, phenyl, pyridine, thiophene, furan, pyrrole, substituted phenyl,
substituted pyridine, substituted thiophene, substituted furan, and
substituted pyrrole;

30 provided that when,

R¹⁴ is 7-azaindazole, 4-azaindazole, 1H-thieno[3,2-c]pyrazole, benzamide,
1-phenylethanone, 2-furancarboxamide, 1-(2-furanyl)ethanone, 2-
thienylcarboxamide, 1-(2-thienyl)ethanone, substituted 7-azaindazole, substituted
4-azaindazole, substituted 1H-thieno[3,2-c]pyrazole, substituted benzamide,
35 substituted 1-phenylethanone, substituted 2-furancarboxamide, substituted 1-(2-
furanyl)ethanone, substituted 2-thienylcarboxamide or substituted 1-(2-

thienyl)ethanone, 2-pyridinecarboxamide, substituted 2-pyridinecarboxamide, (methylsulfonyl)benzene, substituted (methylsulfonyl)benzene,
R¹⁵ may additionally be hydrogen;

5 further provided that when

R¹⁴ is isoquinoline,

R¹⁵ is not furyl or alkyl.

8. A pharmaceutically acceptable salt, hydrate, solvate or pro-
10 drug of a compound of Formula (II), as described in claim 7.

9. A compound of claim 1 selected from:

(S)-1-Benzyl-2-[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-ethylamine;

15

(S)-1-Benzyl-2-[6-furan-2-yl-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(S)-1-Benzyl-2-[5,6-bis-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

20

(S)-1-Benzyl-2-[6-thiophen-2-yl-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(S)-1-Benzyl-2-[6-(4-chlorophenyl)-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

25

(S)-1-Benzyl-2-[6-(3-chlorophenyl)-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

30 (S)-1-Benzyl-2-[6-benzyl-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(S)-1-Benzyl-2-[6-cyclopent-1-enyl-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

35 (S)-1-Benzyl-2-[6-cyclopentyl-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(S)-1-Benzyl-2-[6-cyclohex-1-enyl-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine;

(S)-1-Benzyl-2-[6-cyclohexyl-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-

5 ethylamine;

3-Methyl-5-[2-phenyl-5-(piperidin-4-ylmethoxy)-pyridin-3-yl]-1H-indazole;

3-[5-(3-Methyl-1H-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-propylamine;

10

(S)-1-Benzyl-2-[5- (3-methyl-1H-indazol-5-yl) -6-(5-methyl-thiophen-2-yl)-pyridin-3-yloxy]-ethylamine;

(S)-1-Benzyl-2-[5- (3-methyl-1H-indazol-5-yl) -6-(5-methyl-furan-2-yl)-pyridin-3-

15 yloxy]-ethylamine;

3-Methyl-5-[2-phenyl-5-(4-pyridin-3-yl-methyl-piperazin-1-yl)-pyridin-3-yl]-1H-indazole;

20

3-Methyl-5-[2-phenyl-5-(4-pyridin-4-ylmethyl-piperazin-1-yl)-pyridin-3-yl]-1H-indazole;

[(1S)-2-{[6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

25

[(1S)-2-{[5-(3-methyl-1H-indazol-5-yl)-6-(5-chloro-2-thienyl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{[6-(3-aminophenyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-

30 (phenylmethyl)ethyl]amine;

(S)-1-Benzyl-2-[5-(1H-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-ethylamine;

(S)-1-Benzyl-2-{6-[3-(3-fluoro-benzyloxy)phenyl]-5- (3-methyl-1H-indazol-5-yl) -

35 pyridin-3-yloxy}-ethylamine;

(S)-1-Benzyl-2-[5-(3-phenyl-1H-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-ethylamine;

[(1S)-2-{{5-(3-methyl-1H-indazol-5-yl)-6-(1H-pyrrol-2-yl)-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

5 N-{3-[5-{{(2S)-2-amino-3-phenylpropyl}oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenyl}benzamide;

N-{3-[5-{{(2S)-2-amino-3-phenylpropyl}oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenyl}-2,6-difluorobenzamide;

10 N-{3-[5-{{(2S)-2-amino-3-phenylpropyl}oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenyl}cyclohexanecarboxamide;

[(1S)-2-{{5-[3-(2-furanyl)-1H-indazol-5-yl]-6-phenyl-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

15 {[(1S)-2-phenyl-1-{{6-phenyl-5-[3-(2-thienyl)-1H-indazol-5-yl]-3-pyridinyl}oxy}methyl]ethyl}amine;

20 [(1S)-2-{{5-[3-(3-furanyl)-1H-indazol-5-yl]-6-phenyl-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{{5-[3-(3-thienyl)-1H-indazol-5-yl]-6-phenyl-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

25 3-[5-{{(2S)-2-amino-3-phenylpropyl}oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenol;

[(1S)-2-{{5-(2,3-dimethyl-2H-indazol-5-yl)-6-phenyl-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

30 [(1S)-2-{{5-(3-cyclopropyl-1H-indazol-5-yl)-6-(3-furanyl)-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

35 [(1S)-2-{{5-(3-methyl-1H-indazol-5-yl)-6-(1-methyl-1H-pyrazol-4-yl)-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{{6-[1-[(3-fluorophenyl)methyl]-1H-pyrazol-4-yl]-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

5 ((1S)-2-phenyl-1-{{[(6-phenyl-5-{3-[5-(1-piperazinylmethyl)-2-furanyl]-1H-indazol-5-yl}-3-pyridinyl}oxy]methyl}ethyl)amine;

[(1S)-2-{{6-(3-furanyl)-5-[3-(2-furanyl)-1H-indazol-5-yl]-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

10 [(1S)-2-{{5-(3-methyl-1H-indazol-5-yl)-6-[3-(phenyloxy)phenyl]-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

3-{{5-[5-(5-{{[(2S)-2-amino-3-phenylpropyl}oxy]-2-phenyl-3-pyridinyl}-1H-indazol-3-yl]-2-furanyl}methyl}amino]propanenitrile ;

15 [(1S)-2-{{6-(2-furanyl)-5-[3-(2-furanyl)-1H-indazol-5-yl]-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

20 {5-[5-{{[(2S)-2-amino-3-phenylpropyl}oxy]-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]-2-thienyl}methanol;

[(1S)-2-phenyl-1-{{[(6-phenyl-5-[3-(phenylmethyl)-1H-indazol-5-yl]-3-pyridinyl}oxy]methyl}ethyl]amine;

25 [(1S)-2-{{5-(3-methyl-1H-indazol-5-yl)-6-(1-methyl-1H-pyrrol-2-yl)-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

5-(5-{{[(2S)-2-amino-3-phenylpropyl}oxy]-2-phenyl-3-pyridinyl}-1H-indazol-3-amine;

30 [(1S)-2-{{5-[3-(1-methylethenyl)-1H-indazol-5-yl]-6-phenyl-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{{5-(3-methyl-1H-indazol-5-yl)-6-(1H-pyrazol-4-yl)-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

35 (2S)-N,N-dimethyl-1-{{5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl}oxy}-3-phenyl-2-propanamine;

[(1S)-2-{[3-(3-methyl-1H-indazol-5-yl)-2,4'-bipyridin-5-yl]oxy}-1-(phenylmethyl)ethyl]amine;

5 [(1S)-2-{[3-(3-methyl-1H-indazol-5-yl)-2,3'-bipyridin-5-yl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{[5-(3-iodo-1H-indazol-5-yl)-6-phenyl-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

10

[(1S)-2-[(5-(3-methyl-1H-indazol-5-yl)-6-{3-[(trifluoromethyl)oxy]phenyl}-3-pyridinyl)oxy]-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{[6-(3,5-dimethyl-4-isoxazolyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

15

4-[5-[(2S)-2-amino-3-phenylpropyl]oxy]-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenol;

20

2-[5-[(2S)-2-amino-3-phenylpropyl]oxy]-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenol;

[(1S)-2-{[6-[3-(ethyloxy)phenyl]-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

25

[(1S)-2-{[5-(3-methyl-1H-indazol-5-yl)-6-[3-(methyloxy)phenyl]-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

{3-[5-[(2S)-2-amino-3-phenylpropyl]oxy]-3-(3-methyl-1H-indazol-5-yl)-2-

30

pyridinyl]phenyl}(phenyl)methanone;

[(1S)-2-{[6-{3-[(1-methylethyl)oxy]phenyl}-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

35

[(1S)-2-{[5-[3-(2-furanyl)-1H-indazol-5-yl]-6-(1H-pyrrol-2-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{{[6-(2-{{[3-fluorophenyl]methyl}oxy}phenyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

5 [(1S)-2-{{[6-(4-{{[3-fluorophenyl]methyl}oxy}phenyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{{5-[3-(5-chloro-2-thienyl)-1H-indazol-5-yl]-6-phenyl-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

10 [(1S)-2-{{5-[3-(4-methyl-2-thienyl)-1H-indazol-5-yl]-6-phenyl-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{{5-[3-(5-methyl-2-furanyl)-1H-indazol-5-yl]-6-phenyl-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

15 [(1S)-2-{{5-[3-(5-methyl-2-thienyl)-1H-indazol-5-yl]-6-phenyl-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{{[6-ethenyl-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

20 [(1S)-2-phenyl-1-{{[6-phenyl-5-[3-(1H-pyrrol-2-yl)-1H-indazol-5-yl]-3-pyridinyl}oxy}methyl]ethyl]amine;

[(1S)-2-(1H-indol-3-yl)-1-{{[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl}oxy}methyl]ethyl]amine;

25 5-(3-methyl-1H-indazol-5-yl)-6-phenyl-N-(3-phenylpropyl)-3-pyridinamine;

[(2S)-2-amino-3-phenylpropyl][5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl]amine;

30 5-(3-methyl-1H-indazol-5-yl)-6-phenyl-N-(3-phenylbutyl)-3-pyridinamine;

[(2S)-2-amino-3-phenylpropyl][6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]amine;

35

((1S)-2-{[6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-[(phenylmethyl)oxy]methyl}ethyl)amine;

5 N-[(2S)-2-amino-3-phenylpropyl]-N-[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl]methanesulfonamide;

10 5-(3-methyl-1H-indazol-5-yl)-N-[2-methyl-2-(phenylthio)propyl]-6-phenyl-3-pyridinamine;

15 [(1S)-2-{[6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

20 ((1S)-2-{[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl]oxy}-1-[(phenylmethyl)oxy]methyl}ethyl)amine;

25 (2S)-2-amino-3-{[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl]oxy}-1-propanol;

30 5-(3-methyl-1H-indazol-5-yl)-6-phenyl-N-[(2S)-2-pyrrolidinylmethyl]-3-pyridinamine;

35 ((2S)-2-amino-3-{4-[(phenylmethyl)oxy]phenyl}propyl)[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl]amine;

[(2S)-2-amino-3-phenylpropyl][5-(1H-indazol-5-yl)-6-phenyl-3-pyridinyl]amine;

40 [(2S)-2-amino-3-phenylpropyl][6-(3-furanyl)-5-(1H-indazol-5-yl)-3-pyridinyl]amine;

45 [(2S)-2-amino-3-phenylpropyl][5-(1H-indazol-5-yl)-6-(3-thienyl)-3-pyridinyl]amine;

50 2-[5-[(2S)-2-amino-3-phenylpropyl]amino]-3-(1H-indazol-5-yl)-2-pyridinyl]phenol;

55 2-[5-[(2S)-2-amino-3-phenylpropyl]amino]-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenol;

60 [(2S)-2-amino-3-phenylpropyl][5-(3-methyl-1H-indazol-5-yl)-6-(1H-pyrrol-2-yl)-3-pyridinyl]amine;

[(2S)-2-amino-3-phenylpropyl][5-(3-methyl-1H-indazol-5-yl)-6-(5-methyl-2-thienyl)-3-pyridinyl]amine;

[(2R)-2-amino-3-phenylpropyl][5-(1H-indazol-5-yl)-6-(3-thienyl)-3-pyridinyl]amine;

5

2-[5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenol;

[(1S)-2-(1H-indol-3-yl)-1-({[5-(3-methyl-1H-indazol-5-yl)-6-(1H-pyrrol-2-yl)-3-

10 pyridinyl]oxy}methyl)ethyl]amine;

[(1S)-2-(1H-indol-3-yl)-1-({[5-(3-methyl-1H-indazol-5-yl)-6-(5-methyl-2-thienyl)-3-pyridinyl]oxy}methyl)ethyl]amine;

15 [(1S)-2-{[6-ethyl-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{[6-(3-furanyl)-5-(1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

20

[(1S)-2-{[5-(3-ethenyl-1H-indazol-5-yl)-6-(3-furanyl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{[5-(3-ethyl-1H-indazol-5-yl)-6-(3-furanyl)-3-pyridinyl]oxy}-1-

25 (phenylmethyl)ethyl]amine;

[(1S)-2-({6-(3-furanyl)-5-[3-(3-pyridinyl)-1H-indazol-5-yl]-3-pyridinyl}oxy)-1-(phenylmethyl)ethyl]amine;

30 [(1S)-2-{[6-methyl-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-({5-(3-methyl-1H-indazol-5-yl)-6-[2-(methyloxy)phenyl]-3-pyridinyl}oxy)-1-(phenylmethyl)ethyl]amine;

35

[(1S)-2-{[6-[2-(ethyloxy)phenyl]-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{[6-[5-chloro-2-(methyloxy)phenyl]-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

5 [(1S)-2-{[6-[5-fluoro-2-(propyloxy)phenyl]-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-({5-[3-(1-methylethyl)-1H-indazol-5-yl]-6-phenyl-3-pyridinyl}oxy)-1-(phenylmethyl)ethyl]amine;

10 [(1S)-2-{[5-(6-fluoro-3-methyl-1H-indazol-5-yl)-6-(3-furanyl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

N-[6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]-L-phenylalaninamide;

15 N-[6-(2-hydroxyphenyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]-L-phenylalaninamide;

20 2-[5-{[(2S)-2-amino-3-(1-benzothien-3-yl)propyl]oxy}-3-(1H-indazol-5-yl)-2-pyridinyl]phenol;

[(1S)-2-(1-benzothien-3-yl)-1-({[6-(2-furanyl)-5-(1H-indazol-5-yl)-3-pyridinyl]oxy}methyl)ethyl]amine;

25 [(1S)-2-{[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl]oxy}-1-(2-naphthalenylmethyl)ethyl]amine;

N-[5-(3-methyl-1H-indazol-5-yl)-6-(1H-pyrrol-2-yl)-3-pyridinyl]-L-phenylalaninamide;

30 [(2S)-2-amino-3-(1H-indol-3-yl)propyl][6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]amine;

(2S)-1-{[6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-3-phenyl-2-propanol;

35 1-{3-[5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-2-(3-furanyl)-3-pyridinyl]phenyl}ethanone;

[(1S)-2-{{6-cyclopentyl-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

5 [(1S)-2-(1-benzothien-3-yl)-1-{{[5-(1H-indazol-5-yl)-6-phenyl-3-pyridinyl]oxy}methyl}ethyl]amine;

[(1S)-2-(1-benzothien-3-yl)-1-{{[6-(3-furanyl)-5-(1H-indazol-5-yl)-3-pyridinyl]oxy}methyl}ethyl]amine;

10 [(1S)-2-(1-benzothien-3-yl)-1-{{[5-(1H-indazol-5-yl)-6-(3-thienyl)-3-pyridinyl]oxy}methyl}ethyl]amine;

[(1S)-2-(1-benzothien-3-yl)-1-{{[5-(1H-indazol-5-yl)-6-(1H-pyrrol-2-yl)-3-pyridinyl]oxy}methyl}ethyl]amine;

15 [(1S)-2-{{[5-(1H-indazol-5-yl)-6-phenyl-3-pyridinyl]oxy}-1-(1H-pyrazol-1-ylmethyl)ethyl]amine;

20 [(1S)-2-{{[5-(1H-indazol-5-yl)-6-(5-methyl-2-thienyl)-3-pyridinyl]oxy}methyl}ethyl]amine;

[(1S)-2-{{[6-(3-furanyl)-5-(3-methyl-1H-thieno[3,2-c]pyrazol-5-yl)-3-pyridinyl]oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

25 5-[5-{{(2S)-2-amino-3-phenylpropyl]oxy}-2-(3-furanyl)-3-pyridinyl]-N-4-pyridinyl-1H-indazol-3-amine;

N-{5-[5-{{(2S)-2-amino-3-phenylpropyl]oxy}-2-(3-furanyl)-3-pyridinyl]-1H-indazol-3-yl}benzamide;

30 (1E)-1-{3-[5-{{(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-2-(3-furanyl)-3-pyridinyl]phenyl}ethanone oxime;

35 [(1S)-2-{{[6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)propyl]amine;

(2S)-N-methyl-1-{[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl]oxy}-3-phenyl-2-propanamine;

5 [(1S)-2-{{[6-[5-fluoro-2-(methyloxy)phenyl]-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{{[6-[3,5-difluoro-2-(methyloxy)phenyl]-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

10 [(1S)-2-{{[6-(3-furanyl)-5-[3-(4-pyridinyl)-1H-indazol-5-yl]-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

2-{{[2S)-2-amino-3-phenylpropyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]-4-fluorophenol;

15 2-{{[2S)-2-amino-3-phenylpropyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]-4,6-difluorophenol;

2-{{[2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(6-fluoro-3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenol;

20 2-{{[2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-ethyl-1H-indazol-5-yl)-2-pyridinyl]phenol;

25 [(1S)-2-{{[5-(3-ethyl-1H-indazol-5-yl)-6-(3-furanyl)-3-pyridinyl]oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

[(1S)-2-{{[5-(3-ethyl-1H-indazol-5-yl)-6-(2-furanyl)-3-pyridinyl]oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

30 [(1S)-2-{{[5-(3-ethyl-1H-indazol-5-yl)-6-(1H-pyrrol-2-yl)-3-pyridinyl]oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

[(1S)-2-{{[6-(3-furanyl)-5-[3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl]-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

35

[(1S)-2-({6-(3-furanyl)-5-[3-(1H-pyrrol-2-yl)-1H-indazol-5-yl]-3-pyridinyl}oxy)-1-(phenylmethyl)ethyl]amine;

5 [(1S)-2-({6-(3-furanyl)-5-[3-(1H-pyrazol-4-yl)-1H-indazol-5-yl]-3-pyridinyl}oxy)-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{{5-(6-fluoro-3-methyl-1H-indazol-5-yl)-6-(2-furanyl)-3-pyridinyl}oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

10 [(1S)-2-{{5-(6-fluoro-3-methyl-1H-indazol-5-yl)-6-(1H-pyrrol-2-yl)-3-pyridinyl}oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

15 [(1S)-2-{{5-(6-fluoro-3-methyl-1H-indazol-5-yl)-6-(3-furanyl)-3-pyridinyl}oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

[(1S)-2-{{6-(1-benzothien-2-yl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

20 [(1S)-2-{{6-(1-benzofuran-2-yl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl}oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-({6-(3-furanyl)-5-[3-(methylsulfonyl)phenyl]-3-pyridinyl}oxy)-1-(1H-indol-3-ylmethyl)ethyl]amine;

25 5-[5-{{(2S)-2-(1-azetidinyl)-3-(1H-indol-3-yl)propyl}oxy}-2-(3-furanyl)-3-pyridinyl]-3-methyl-1H-indazole;

[(1S)-2-({6-(3-furanyl)-5-[3-(1H-pyrazol-4-yl)-1H-indazol-5-yl]-3-pyridinyl}oxy)-1-(1H-indol-3-ylmethyl)ethyl]amine;

30 3-[5-{{(2S)-2-amino-3-(1H-indol-3-yl)propyl}oxy}-2-(3-furyl)pyridin-3-yl]benzamide;

4-[5-{{(2S)-2-amino-3-(1H-indol-3-yl)propyl}oxy}-2-(3-furyl)pyridin-3-yl]benzamide;

35 5-(5-{{(2S)-3-(1H-indol-3-yl)-2-(1-piperidinyl)propyl}oxy}-2-phenyl-3-pyridinyl)-3-methyl-1H-indazole;

5-(2-(3-furanyl)-5-{{(2S)-3-(1H-indol-3-yl)-2-(4-morpholinyl)propyl]oxy}-3-pyridinyl)-3-methyl-1H-indazole;

5 [(1S)-2-{{6-(3-furanyl)-5-[3-(1H-pyrazol-4-yl)-1H-indazol-5-yl]-3-pyridinyl}oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

10 [(1S)-2-{{6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl}oxy}-1-(1H-indol-3-ylmethyl)ethyl]dimethylamine;

15 (3S)-3-{{6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl}oxy}methyl)-2-methyl-2,3,4,9-tetrahydro-1H-carboline;

20 1-{5-[5-{{(2S)-2-amino-3-(1H-indol-3-yl)propyl}oxy}-2-(3-furanyl)-3-pyridinyl]-2-thienyl}ethanone;

25 (2S)-1-{{6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl}oxy}-3-(1H-indol-3-yl)-N-methyl-2-propanamine;

30 5-[5-{{(2S)-2-amino-3-(1H-indol-3-yl)propyl}oxy}-2-(3-furanyl)-3-pyridinyl]-N,N-dimethyl-2-furancarboxamide;

35 5-[5-{{(2S)-2-amino-3-(1H-indol-3-yl)propyl}oxy}-2-(3-furanyl)-3-pyridinyl]-N-methyl-2-furancarboxamide;

40 [(2S)-2-amino-3-phenylpropyl]{{6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl}methylamine;

45 [(1S)-2-(3,4-dichlorophenyl)-1-{{5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl}oxy}methyl]ethylamine;

50 N-[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl]-L-phenylalaninamide;

55 N-[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-3-pyridinyl]-L-phenylalaninamide;

2-[5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]amino]-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]-4-fluorophenol;

5 ((1S)-3-[[6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy]-1-[[4-(trifluoromethyl)phenyl]methyl]propyl)amine;

[(1S)-3-[[6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy]-1-(1H-indol-3-ylmethyl)propyl]amine;

10 {(1S)-2-[[6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy]-1-[(5-methyl-1H-indol-3-yl)methyl]ethyl}amine;

[(1S)-2-(1H-indol-3-yl)-1-[[5-(3-methyl-1H-indazol-5-yl)-6-(1H-pyrrol-3-yl)pyridin-3-yl]oxy]methyl]ethyl]amine;

15 [(1S)-2-[[6-(3-furanyl)-5-(3-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-3-pyridinyl]oxy]-1-(1H-indol-3-ylmethyl)ethyl]amine;

[(1S)-2-(1H-indol-3-yl)-1-[[5-(3-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-3-pyridinyl]oxy]methyl]ethyl]amine;

20 5-[5-[(2S)-2-amino-3-phenylpropyl]oxy]-2-(3-furanyl)-3-pyridinyl]-1H-indazole-3-carboxamide;

25 5-[5-[(2S)-2-amino-3-phenylpropyl]oxy]-2-(3-furanyl)-3-pyridinyl]-1H-indazole-3-carbonitrile;

(2S)-1-[[6-(2-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy]-3-(1H-indol-3-yl)-2-propanamine;

30 2-[5-[(2S)-2-amino-3-(1-benzothien-3-yl)-3-propyl]oxy]-3-(1H-indazol-5-yl)-2-pyridinyl]-4-fluorophenol;

35 2-[5-[(2S)-2-amino-3-(1-benzothien-3-yl)-3-propyl]oxy]-3-(1H-indazol-5-yl)-2-pyridinyl]-4,6-difluorophenol;

[(1S)-2-(1-benzothien-3-yl)-1-({[5,6-bis(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}methyl)ethyl]amine;

5 [(1S)-2-(1-benzothien-3-yl)-1-({[4-(3-furanyl)-3-(3-methyl-1H-indazol-5-yl)phenyl]oxy}methyl)ethyl]amine;

4'-{[(2S)-2-amino-3-(1-benzothien-3-yl)propyl]oxy}-3,5-difluoro-2'-(3-methyl-1H-indazol-5-yl)-2-biphenylo; 10

4'-{[(2S)-2-amino-3-(1-benzothien-3-yl)propyl]oxy}-5-fluoro-2'-(3-methyl-1H-indazol-5-yl)-2-biphenylo;

15 2-[5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]-4,6-difluorophenol;

[(2S)-2-amino-3-(1H-indol-3-yl)propyl][5-(3-methyl-1H-indazol-5-yl)-6-(1H-pyrrol-2-yl)-3-pyridinyl]amine;

20 [(2S)-2-amino-3-(1H-indol-3-yl)propyl][6-[5-fluoro-2-(methyloxy)phenyl]-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]amine;

25 2-[5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]amino}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenol;

[(2S)-2-amino-3-(5-fluoro-1H-indol-3-yl)propyl][6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]amine;

30 [(2S)-2-amino-4-pentyn-1-yl][6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]amine;

35 [(2S)-2-amino-3-(5,6,7-trifluoro-1H-indol-3-yl)propyl][6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]amine;

[(2S)-2-amino-3-(5,7-difluoro-1H-indol-3-yl)propyl][6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]amine;

[(1S)-2-{[6-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(1H-pyrrolo[2,3-*b*]pyridin-2-ylmethyl)ethyl]amine;

[(2R)-2-amino-3-phenylpropyl][3-fluoro-4-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)phenyl]amine;

[(2R)-2-amino-3-(1H-indol-3-yl)propyl][3-fluoro-4-(3-furanyl)-5-(3-methyl-1H-indazol-5-yl)phenyl]amine;

[(1S)-2-{[6-(3-furanyl)-5-(3-methyl-1H-pyrazolo[3,4-*b*]pyridin-5-yl)-3-pyridinyl]oxy}-1-(1H-indol-3-ylmethyl)ethyl]amine;

[(1S)-2-(1H-indol-3-yl)-1-{[6-(2-methyl-3-furanyl)-5-(3-methyl-1H-pyrazolo[3,4-*b*]pyridin-5-yl)-3-pyridinyl]oxy}methyl]ethyl]amine;

[(1S)-2-(1H-indol-3-yl)-1-{[5-(3-methyl-1H-pyrazolo[3,4-*b*]pyridin-5-yl)-6-phenyl-3-pyridinyl]oxy}methyl]ethyl]amine;

[(1S)-2-{[6-(3-furanyl)-5-(3-methyl-1H-pyrazolo[3,4-*b*]pyridin-5-yl)-3-pyridinyl]oxy}-1-(1H-indol-3-ylmethyl)ethyl]methylamine;

2-[5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-pyrazolo[3,4-*b*]pyridin-5-yl)-2-pyridinyl]phenol;

2-[5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-pyrazolo[3,4-*b*]pyridin-5-yl)-2-pyridinyl]-6-fluorophenol;

[(1S)-2-{[5-[3-(3,5-dimethyl-4-isoxazolyl)-1H-indazol-5-yl]-6-(3-furanyl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{[6-(3-furanyl)-5-[3-(2-pyridinyl)-1H-indazol-5-yl]-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{[6-(2-chlorophenyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{[5-(3-methyl-1H-indazol-5-yl)-6-(2-methylphenyl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-{[6-(2-fluorophenyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

10 2-[5-{[(2S)-2-amino-3-phenylpropyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]-4-chlorophenol;

[(1S)-2-{[6-(1-benzothien-3-yl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

15 3-[5-{[(2S)-2-amino-3-phenylpropyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]benzamide;

3-[5-{[(2S)-2-amino-3-phenylpropyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]benzonitrile;

[(1S)-2-{[5-(3-methyl-1H-indazol-5-yl)-6-(3-nitrophenyl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

25 [(1S)-2-{[5-(3-methyl-1H-indazol-5-yl)-6-(4-methyl-2-thienyl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

N-{3-[5-{[(2S)-2-amino-3-phenylpropyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenyl}-N'-phenylurea;

30 [(1S)-2-{[5-(3-methyl-1H-indazol-5-yl)-6-(2-thienyl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine;

[(1S)-2-(1H-indol-3-yl)-1-({[6-(2-methyl-3-furanyl)-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy}methyl)ethyl]amine;

{2-[5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]phenyl}amine;

2-[5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]-6-fluorophenol;

2-[5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]-4-chlorophenol;

2-[5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-indazol-5-yl)-2-pyridinyl]-4-fluorophenol;

[(1S)-2-[[6-[3,5-difluoro-2-(methyloxy)phenyl]-5-(3-methyl-1H-thieno[3,2-c]pyrazol-5-yl)-3-pyridinyl]oxy]-1-(1H-indol-3-ylmethyl)ethyl]amine;

2-[5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-thieno[3,2-c]pyrazol-5-yl)-2-pyridinyl]-4,6-difluorophenol;

2-[5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-thieno[3,2-c]pyrazol-5-yl)-2-pyridinyl]phenol;

2-[5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-3-(3-methyl-1H-thieno[3,2-c]pyrazol-5-yl)-2-pyridinyl]-4-chlorophenol;

3-(5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy)-3-pyridinyl)benzamide;

1-[3-(5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy)-3-pyridinyl]phenyl]ethanone; and

5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-2-(3-furanyl)-3,4'-bipyridine-2'-carboxamide.

10. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (II), as described in claim 9.

11. A pharmaceutical composition comprising a compound according to claim 1, and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof and a pharmaceutically acceptable carrier.

12. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of Formula (I) as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof, which process comprises bringing the compound of Formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof into association with a pharmaceutically acceptable carrier or diluent.

10 13. A method of treating or lessening the severity of cancer in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of Formula I, as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

15 14. The method of claim 13 wherein the mammal is a human.

15. A method of treating or lessening the severity of cancer in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of Formula II, as described in claim 20 5 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

16. The method of claim 15 wherein the mammal is a human.

17. The method according to claim 13 wherein said cancer is selected from brain (gliomas), glioblastomas, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma and thyroid.

30 18. The method according to claim 15 wherein said cancer is selected from brain (gliomas), glioblastomas, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma and thyroid.

35 19. Use of a compound of Formula (I), as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof, in the manufacture of a medicament for use in treating or lessening the severity of cancer.

20. The method of inhibiting Akt activity in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of Formula I, as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

5

21. The method of claim 20 wherein the mammal is a human.

22. A method of treating cancer in a mammal in need thereof, 10 which comprises: administering to such mammal a therapeutically effective amount of

- a) a compound of Formula (I), as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof; and
- b) at least one anti-neoplastic agent.

15

23. The method of claim 22, wherein the at least one anti-neoplastic agent is selected from the group consisting essentially of anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, 20 hormones and hormonal analogues, signal transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; proapoptotic agents; and cell cycle signaling inhibitors.

24. The method of claim 22, wherein the at least one anti-neoplastic agent is an anti-microtubule agent selected from diterpenoids and vinca alkaloids.

25

25. The method of claim 22, wherein the at least one anti-neoplastic agent is a diterpenoid.

30

26. The method of claim 22, wherein the at least one anti-neoplastic agent is a vinca alkaloid.

27. The method of claim 22, wherein the at least one anti-neoplastic agent is a platinum coordination complex.

35

28. The method of claim 22, wherein the at least one anti-neoplastic agent is paclitaxel, carboplatin, or vinorelbine.

29. The method of claim 22, wherein the at least one anti-
5 neoplastic agent is paclitaxel.

30. The method of claim 22, wherein the at least one anti-neoplastic agent is carboplatin.

10 31. The method of claim 22, wherein the at least one anti-neoplastic agent is vinorelbine.

32. The method of claim 22, wherein the at least one anti-neoplastic agent is a signal transduction pathway inhibitor.

15 33. The method of claim 32, wherein the signal transduction pathway inhibitor is an inhibitor of a growth factor receptor kinase selected from the group consisting of VEGFR2, TIE2, PDGFR, BTK, IGFR-1, TrkA, TrkB, TrkC, and c-fms.

20 34. The method of claim 32, wherein the signal transduction pathway inhibitor is an inhibitor of a serine/threonine kinase selected from the group consisting of rafk, akt, and PKC-zeta.

25 35. The method of claim 32, wherein the signal transduction pathway inhibitor is an inhibitor of a serine/threonine kinase selected from the src family of kinases.

30 36. The method of claim 35, wherein the signal transduction pathway inhibitor is an inhibitor of c-src.

37. The method of claim 32, wherein the signal transduction pathway inhibitor is an inhibitor of Ras oncogene selected from inhibitors of farnesyl transferase and geranylgeranyl transferase.

35

38. The method of claim 32, wherein the signal transduction pathway inhibitor is an inhibitor of a serine/threonine kinase selected from the group consisting of PI3K.

5 39. The method of claim 22, wherein the at least one anti-neoplastic agent is a cell cycle signaling inhibitor.

40. The method of claim 39, wherein the cell cycle signaling inhibitor is selected from inhibitors of the group CDK2, CDK4, and CDK6.

10 41. A pharmaceutical combination as claimed in claim 22 for use in therapy.

15 42. The use of a pharmaceutical combination as claimed in claim 22 for the preparation of a medicament useful in the treatment of cancer.

20 43. A method of treating or lessening the severity of arthritis in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of Formula I, as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

44. The method of claim 43 wherein the mammal is a human.

25 45. A method of treating or lessening the severity of arthritis in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of Formula II, as described in claim 5 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

46. The method of claim 45 wherein the mammal is a human.

30 47. Use of a compound of Formula (I), as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof, in the manufacture of a medicament for use in treating or lessening the severity of arthritis.

35

38. The method of claim 32, wherein the signal transduction pathway inhibitor is an inhibitor of a serine/threonine kinase selected from the group consisting of PI3K.

5 39. The method of claim 22, wherein the at least one anti-neoplastic agent is a cell cycle signaling inhibitor.

40. The method of claim 39, wherein the cell cycle signaling inhibitor is selected from inhibitors of the group CDK2, CDK4, and CDK6.

10 41. A pharmaceutical combination as claimed in claim 22 for use in therapy.

15 42. The use of a pharmaceutical combination as claimed in claim 22 for the preparation of a medicament useful in the treatment of cancer.

20 43. A method of treating or lessening the severity of arthritis in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of Formula I, as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

44. The method of claim 43 wherein the mammal is a human.

25 45. A method of treating or lessening the severity of arthritis in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of Formula II, as described in claim 5 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

46. The method of claim 45 wherein the mammal is a human.

30 47. Use of a compound of Formula (I), as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof, in the manufacture of a medicament for use in treating or lessening the severity of arthritis.